The purpose of this study is to investigate the efficacy and safety of the Ahmed valve implant (AVI) and the Molteno single-plate implant (MSPI) in eyes with refractory glaucoma during a follow-up period of 24 months.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
72
184 mm2 surface area Ahmed Glaucoma Valve (AGV Model FP7; New World Medical Inc., Rancho Cucamonga, California, USA)
134 mm2 surface area single-plate Molteno implant (Molteno Ophthalmic Limited, Dunedin, New Zealand)
Vanak Eye Surgery Center
Tehran, Tehran Province, Iran
Intra Ocular pressure (IOP)
Time frame: Month 24
Intra Ocular pressure (IOP)
Time frame: day 1,week 1, and months 1, 3, 6, 9, 12 and 18
Changes in visual acuity
Time frame: day 1,week 1, and months 1, 3, 6, 9, 12, 18, and 24.
Number of anti-glaucoma medications
Time frame: week 1, and months 1, 3, 6, 9, 12, 18, and 24
Mean deviation of visual field,
Time frame: week 1, and months 1, 3, 6, 9, 12, 18, and 24
Rate of intra- and postoperative complications
Time frame: week 1, and months 1, 3, 6, 9, 12, 18, and 24
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.